0001104659-20-001982.txt : 20200107 0001104659-20-001982.hdr.sgml : 20200107 20200107160549 ACCESSION NUMBER: 0001104659-20-001982 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20200107 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200107 DATE AS OF CHANGE: 20200107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: COLLEGIUM PHARMACEUTICAL, INC CENTRAL INDEX KEY: 0001267565 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37372 FILM NUMBER: 20513382 BUSINESS ADDRESS: STREET 1: 100 TECHNOLOGY CENTER DRIVE CITY: STOUGHTON STATE: MA ZIP: 02072 BUSINESS PHONE: 781-713-3699 MAIL ADDRESS: STREET 1: 100 TECHNOLOGY CENTER DRIVE CITY: STOUGHTON STATE: MA ZIP: 02072 FORMER COMPANY: FORMER CONFORMED NAME: COLLEGIUM PHARMACEUTICAL INC DATE OF NAME CHANGE: 20031020 8-K 1 tm201411-1_8k.htm FORM 8-K
0001267565 false 0001267565 2020-01-06 2020-01-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 7, 2020

 

 

COLLEGIUM PHARMACEUTICAL, INC.

(Exact name of registrant as specified in its charter)

 

Virginia   001-37372   03-0416362
(state or other jurisdiction
of incorporation) 		  (Commission
 File Number) 		  (I.R.S. Employer
Identification No.)

 

    

100 Technology Center Drive

Suite 300

Stoughton, MA

  02072
(Address of principal executive offices)  (Zip Code)

 

Registrant’s telephone number, including area code: (781) 713-3699

 

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicated by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock, par value $0.001 per share COLL The NASDAQ Global Select Market

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure

 

On January 7, 2020, Collegium Pharmaceutical, Inc. (the “Company”) issued a press release announcing full-year revenue and operating expense guidance for 2020. A copy of the press release is attached hereto as Exhibit 99.1 and is being furnished, not filed, under Item 7.01 of this Current Report on Form 8-K.

 

To the extent that the information in this report and Exhibit 99.1 are not descriptions of historical facts regarding the Company, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “anticipate,” “estimate,” “forecast,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this report, including Exhibit 99.1, include, among others, statements regarding full-year 2020 guidance for Xtampza ER and Nucynta Franchise revenues and total operating expense. Forward-looking statements in this report, including Exhibit 99.1, involve substantial risks and uncertainties that could cause our future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the following: our ability to maintain regulatory approval of our products, and any related restrictions, limitations, and/or warnings in the label of an approved product; our plans to commercialize and grow sales of our products; our ability to effectively commercialize in-licensed products and manage our relationships with licensors; the success of competing products that are or become available; our ability to obtain and maintain reimbursement and third-party payor contracts for our products; the rate and degree of market acceptance of our products; changing market conditions for our products; the outcome of any patent infringement or other litigation that may be brought by or against us, including litigation with Purdue Pharma, L.P. and Teva Pharmaceuticals USA, Inc.; regulatory developments impacting our products and market; our expectations regarding our ability to obtain and maintain sufficient intellectual property protection for our products and product candidates; our ability to operate our business without infringing the intellectual property rights of others; the performance of our third-party suppliers and manufacturers; our ability to secure adequate supplies of active pharmaceutical ingredient for each of our products; our ability to comply with stringent government regulations relating to the manufacturing and marketing of pharmaceutical products, including U.S. Drug Enforcement Agency, or DEA, compliance; the loss of key scientific or management personnel; and the accuracy of our estimates regarding expenses, revenue, capital requirements and need for additional financing. These and other risks, uncertainties and factors are described under the heading “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, and those risks described from time to time in other reports which we file with the SEC. Any forward-looking statements that we make in this report, including Exhibit 99.1, speak only as of the date of this report. The Company assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this report.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
No. 		  Description
   
99.1   Press Release dated January 7, 2020.
     
104   Cover Page Interactive Data File - the cover page XBRL tags are embedded within Inline XBRL document.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Collegium Pharmaceutical, Inc.
   
  By: /s/ Paul Brannelly  
    Paul Brannelly
    Executive Vice President and Chief Financial Officer

 

Dated: January 7, 2020

 

 

 EX-99.1 2 tm201411d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

Collegium Provides 2020 Financial Guidance

 

– Xtampza® ER Revenues Expected in the Range of $150.0 Million to $160.0 Million for 2020 –

 

STOUGHTON, Mass., Jan. 7, 2020 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today provided full-year 2020 guidance for Xtampza® ER product revenues, Nucynta® franchise product revenues and total operating expenses.

 

“In 2020, Xtampza ER is well-positioned for the next stage of growth driven by the 15 new exclusive extended-release oxycodone formulary wins covering more than 35 million lives that took effect on January 1, 2020,” said Joe Ciaffoni, President and Chief Executive Officer of Collegium. “Xtampza ER growth, as well as a commitment to leverage our existing cost structure, will drive Collegium to profitability in 2020.”

 

Financial Guidance for 2020

 

·Xtampza ER revenues are expected in the range of $150.0 million to $160.0 million.
·Nucynta franchise revenues are expected in the range of $170.0 million to $180.0 million.
·Total operating expenses are expected in the range of $130.0 million to $140.0 million.

 

About Collegium Pharmaceutical, Inc.

 

Collegium is a specialty pharmaceutical company committed to being the leader in responsible pain management. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the company’s website at www.collegiumpharma.com.

 

About Xtampza ER

 

Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

 

About Nucynta ER

 

Nucynta® ER is an extended-release formulation of tapentadol. Tapentadol is a centrally acting synthetic analgesic. Nucynta ER is approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Nucynta ER is also approved by the FDA for neuropathic pain associated with diabetic peripheral neuropathy severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

 

 

 

 

About Nucynta

 

Nucynta® is an immediate release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. Tapentadol is a centrally acting synthetic analgesic.

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding financial guidance for Xtampza ER and Nucynta Franchise revenues, total operating expenses, current and future market opportunities for our products and our assumptions related thereto. Such statements are subject to numerous important factors, risks and uncertainties that may cause our future results, performance, or achievements to differ materially from the company's current expectations. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including our ability to obtain and maintain regulatory approval of our products and product candidates; our ability to effectively commercialize in-licensed products and manage our relationships with licensors; the success of competing products that are or become available; our ability to obtain reimbursement and third-party payor contracts for our products; the rate and degree of market acceptance of our products and product candidates; the outcome of any patent infringement or other litigation that may be brought by or against us, including litigation with Purdue Pharma, L.P. and Teva Pharmaceuticals USA, Inc.; the outcome of any governmental investigation related to the manufacture, marketing and sale of opioid medications; our ability to secure adequate supplies of active pharmaceutical ingredient for each of our products and product candidates and manufacture adequate supplies of our products; our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including U.S. Drug Enforcement Agency, or DEA, compliance; and the accuracy of our estimates regarding expenses, revenue, capital requirements and need for additional financing. These and other risks are described under the heading "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, and in other reports which we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

 

Contact:
Alex Dasalla
adasalla@collegiumpharma.com

 

 

 

 GRAPHIC 3 tm201411d1_ex99-1img01.jpg GRAPHIC begin 644 tm201411d1_ex99-1img01.jpg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end EX-101.SCH 4 coll-20200107.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 coll-20200107_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 coll-20200107_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 tm201411-1_8k_htm.xml IDEA: XBRL DOCUMENT 0001267565 2020-01-06 2020-01-07 iso4217:USD shares iso4217:USD shares 0001267565 false 8-K 2020-01-07 COLLEGIUM PHARMACEUTICAL, INC. VA 001-37372 03-0416362 100 Technology Center Drive Suite 300 Stoughton MA 02072 781 713-3699 false false false false false Common stock, par value $0.001 per share COLL NASDAQ XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Cover
Jan. 07, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 07, 2020
Entity File Number 001-37372
Entity Registrant Name COLLEGIUM PHARMACEUTICAL, INC.
Entity Central Index Key 0001267565
Entity Tax Identification Number 03-0416362
Entity Incorporation, State or Country Code VA
Entity Address, Address Line One 100 Technology Center Drive
Entity Address, Address Line Two Suite 300
Entity Address, City or Town Stoughton
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02072
City Area Code 781
Local Phone Number 713-3699
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol COLL
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
JSON 10 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm201411-1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "tm201411-1_8k.htm" ] }, "labelLink": { "local": [ "coll-20200107_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "coll-20200107_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "coll-20200107.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 0, "memberStandard": 0, "nsprefix": "coll", "nsuri": "http://collegiumpharma.com/20200107", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm201411-1_8k.htm", "contextRef": "From2020-01-06to2020-01-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://collegiumpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm201411-1_8k.htm", "contextRef": "From2020-01-06to2020-01-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r9" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r11": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r12": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r13": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r14": { "Name": "Forms 20-F, 40-F", "Number": "249", "Publisher": "SEC", "Section": "220 and 240", "Subsection": "f" }, "r15": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r18": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" } }, "version": "2.1" } EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 1 97 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://collegiumpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm201411-1_8k.htm coll-20200107.xsd coll-20200107_lab.xml coll-20200107_pre.xml tm201411d1_ex99-1.htm http://xbrl.sec.gov/dei/2019-01-31 true false ZIP 15 0001104659-20-001982-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-20-001982-xbrl.zip M4$L#!!0 ( +B )U#CML)62@, *0, 1 8V]L;"TR,#(P,#$P-RYX M'Q/GP? 3Y).[_E"/9%):]*[TW_B MZO@)7H;)T[#6>WPA7R8##EYG^&OR^<=G<7MS =Y-=F1#!4.("#)O@JNF,U?= MZ+ BY, ]\#S??;YM=U.0XYYDA?2A:[=[1,%4 MV>S2#7C*E28\6,"'>DJ8!U?=;',!2DNA1QF4%M 0EG *@LI O+IFP^#]&O9\ M?.@7\$3A 2'QE-(GJI=*YQLE%"7U*MP$RZ%83V)0I81LJX06",:F#/L YI$ M\9#(B!C'1H9B7ZYW;+J.001<7PL974&?),SD]CLAC/8IA [21 Y 6P^JF 2P MG6CA9\*Y,+8WC9=';"R.J?&U";QK6 /4I6#PW=2![,*TV\8C+,:]%&9P.(B& M32=;6C$CG8C;-LIL66:94IIN,O@.8E$0?B-GZ7K6((RO+2( MM@GDQ!RRAA00%B1L-\XLE5)*'B@N:W9]11/=0Q^ES5>WIF@ZBMK9Y^2QH81^ MT[$WBHNW]-.45C%V*2!6>D/SI3>_?!OYP84$D<&*RLIP,"(B!JFI<>[;<-#JSH=\602JU@6*?<,'#-H3] S-C*F,5SC+=)8G9#>R61,';(XF- [PL M"[6.9!=XQMXV@8U_!VNN(3V_E.@"TZJ(O#&;U?^._=-)M?;(9^&%AUJZ5LCE M@F-NQK6DP796F6=V,J+U2LUZQ3]Z8S+[);)W%@OF"T3"M9S8RS[>R;7SQ.(! MSU1V]LORU\E65BE(F4WL]\H;'%O^N;-G'NO]VG S2;/\"U!+ P04 " "X M@"=0-@B*BOP* #?AP %0 &-O;&PM,C R,# Q,#=?;&%B+GAM;,V=76_C MN!6&[POT/[#>FQ88QW&"+9#LS"XRGF1A;#9)8\]LVT6QH"7&$4*3 24G]K\O M*8FR1/%(2HJ2S$5&([Z'>BD^(:D/4A]_VFTH>B$B33C[-)H>'8\081&/$[;^ M-/JZ&%\L9O/Y"*499C&FG)%/(\9'/_WXYS\A^?/Q+^,QNDH(C<_1%QZ-Y^R! M_X!N\(::8D(S*A./ Y^OYH&J/Q>$"V MWPB+N?AZ/Z^R?_5C@E2)XLEI[OTN33J';4U],C+M:3D^/CZ>2?OUXOHD>RP>.$J9,6 MD9&.4KG8XJ9G9V>3/%5+6\K=2E!]C-.)ME/E+%.3#GW-29JZ9.?GT'!*;DG#R@OYGFV?Y8Q3DP6Z&"C%1\1-&UC@CL3K0F3K0]._J0-^5NZ_QBM 14DI)!UBNLT9>9=#$ MM=D[(A(>7[+WN3:C/=F7?SLB^Q\*4(]W7H0ESS!]E_EZI'/;-^1]9_P0Y_Y, MRT:>O.],UR+_+[:SMN4WGU[[>:5JY[7<:E@DNTQV7R36)E46'2UP?H2\8RCS MKG+G42-?JEIS+MIE3V6^>9XIB8[6_&42DT3F/3U3&V.U,3Z>EBWV=W+7'S,N M!P,7JS03.,IT?GEA/HTLZ1/3F%)>".T.BZBGB*5B$G'903UG8UJ/E86KBA>6PIAI+NJ:*LM7=.-Q""JVN;(K.M*@Y3(;V5_(6DDDF7)(#9UN6)H0N*%L 0F$*.! HE'H2NY+.PIIT;K&!+1KHM(2!H4+Y Y$I@C0Y.0A 6#S M+X+%,&AJ2C_(M*S:@:ED >)B>NN#1>D]HC+;"M'P#O=!L-39@]X>L]4S7T 7 M!"X]YEI/@@MY Q>O?=(ERY)LKU[6N]EN5D18BMB6N"($,J?),-.#( (P99)0 MR)#2H4+HL?[UTP:6J5X7L@=+U]*Y)0.PV43#$ 7$AMT9 $5D"]6V1Z;#?) M <0! =3M$.!(!J%FE'^8\:UL$O@\[RE0>%SND; M"GSJ'YW3H>B4$-R+]@ IJWL&-KP +(;[*.H&B[K./\H ME0/WWC\8+?/3XC1-VIN;0A,>*DUCO0U-H?8/QAU/,TS_G3QW7K+;Q5X@L1JV MHM)0A@>,S5X?-D4,DD'^+L%+=-6#$>L$-R/=W51EBZW#5.5:8A HV!RUIRH7 M=UL*D9_*5KP*@H'6H9GLK*HMIJJ:KJ6%4=%M0ZUZSO_&I<;?'[5:EX;>/7(& MOWK0EKBJ;\BC]?K9"1VAOT6IJS'M^T4W7P.B&( M.C;=M+IOG>ZE3G\322://^.;S9:5SXQL;RH".E=UW6E3U[M5% 0#7)-"%E"/($$F@=P:NE#A HRV8M6$>B?L 6)MK+?W$]/5LLDH[;+T+;$ M62\%F*OZ*",]"$( 4R81>1KB#VAZ\M?5WY".\@+!#5\*K%;'7>PW*TZ!];2L M*EY[@QL)LT.H:X) H0.8ZT+EU**M-;?U(A#5[;N M'QRLO0T.UCV#@W6(@X/UT,'!VO/@0!^\6.A$ME2W*YJL,; 8Z?:-1H=EDU* M+-*@@(']@>U'%8(.,7[6[LP7<%,?*!";W,65W+"4%= Y6[VSRV:U?*=-% 0I M7_"ULK!>C<\@/8 M;')CB +BQ>X,X*02HT+M1<1'F=!)H1]26-Y(5\P1DN'8*EAN2NIWUVF3;G>]JT 8'4:1"< MX5G%J 5OL";+\\(W8B8'8FO>\::ZH7*__$W+8GL%G$H2$"0V7QWKX BDM1Z) M6&PPI9^W:<)("G=-ALHM$5:+32(:DH"(L/D"B,BE2&L]$G&Y(6(MN[V?!7_- M'LM5:<$2 FJWA'1:;I)BE09$3)<_@!P=@HH8O9"P3X1VAX75B_4DX?):I([A M AN>!2$7Z7YFIOM0_/ !LB!R/FRT& MC6%S31$$*: M:-!<_W*"SY4!MRN:1%>48_BN3$/C>#W MCUC*<"#(" .VJZ@ M!0!S(=-16HR-2@T(-K> MXA?@\) %JN7QH=:'^;\%J%Y<5VO5\>AI\8CE:;S=9JGJ6:4]^#YZ9Y#C!Q0# M"F \INB(" C 3:A1Q9Y),I#/Z B&-6BO5[#I8>5#DG\>7]/'HA0,R"69)=] MEH=[ZK@*&1#K^@IO<'',"[[>P"!0?*M;Z'(P1?4,T$J]B59F@7Y7F: \%]NW MX>N[KN66W*UWR5\KG!*YY[]02P,$% @ N( G4&N=:T!;!P 0ED !4 M !C;VQL+3(P,C P,3 W7W!R92YX;6S-G%USVC@4AN]W9O^#EUZ;CV2[W=!D M.PD-':9IDPVTW=V;CK %:")+C"0'^//1,E6927#4ZS78CHB*1*1/3J\:787P][ T&C4@;(E+"I:!7#2$;[_[Z M]9?(_KG\+8ZC/J,\[4;O91(/Q$2^C3Z3C':C#U1018Q4;Z.OA.=NB^PS3E74 MD]F<4T/M%^6!N]'K9B>-XABPVZ]4I%)]>1QL=SLS9MYMM1:+15/(9[*0ZDDW M$PG;W= 0D^OMOMK+]OI/V?R2,_'4=7^-B::1A25T=ZG956/GJ(OSIE33UEF[ MW6G]\^ENF,QH1F(F'+2$-C:MW%ZJVG4N+BY:Q;<;Z9%R.59\PY1=/-CMSQ3PS0,./: MK$^=3A2[\RS/["'MQU*YCF<3$9?)7A#.'8Q:!M$05W3I#F5SZV4,DN_ M<^$^Q.Y#W.ZLF;^RF[X7A[L>:Z-(8C;[XV1,>7&4[U9S(&G]M-@V5$9VO]6A M[2L.(]O-X[5*(JE2JBSWS;Z(2O:R=WS*KA6M.5%V1W$R8WR;^(F2F8_1FH?T M!+J+RQ[B9S*]ME&D+I(^)]-JJ <2(-4.!M9*-[AT"PI/$R#^<\R^(^@6-0_70N2$/]*Y5#7X M]Y5 ZK]C4J_RA@K[[YPH0Q5?07@?B8'(7V,B]SA$I3Y21&CF*$&P'ZN!W/] MO3GQ>$0%/YQ1SET-2 3HC*_2 ^&_P83O]_EB\-\^NWL >^&!9V"G"3 )?[Z4 M)!RY1^(H>!12M@:BRC8>[E2>R$%^QF_ M&@H>I7BM,XE"_E889E9N>.%SGHU_/)C=)WZL@I)&*5A]IA );YY8"..&3T*4 M#Y50TBAU:L@<(NV>=:4('XB4+C_250CWD13*&Z4^#=I#!/Z@6$;4:LB2^F[D M6 M%CE*5A@TB,A^1Y2"UWMB$E4.2]>B]3: 90"E)0781$S$0B51SN?,XNB=S M^PM=]60:[.IK&D*3@E*KGF =,377:6JAZ?4_=TS03B@AE7+P>!1>&@(V7Q3\ ML]/@G\'AH]2PM39?%/SST^"?P^&CU+&U-O'A]^S'>S62"\_XMU<,!8]2Q]98 MQ,=>7(?NU8.2SZRD%& >?O@F.!U(H)11ZMQ*.SA@7;85)?Y3 M>5\!Q8I2O%:90:%Z)]TXRTR*X)/>8Q64+DH5ZC.%TR&[^=#:VQGL? V>8X?2 MW1[:0('Y33%CX^C)+,O%^HF/9QS.(X5"1BD=@_90@ \E9PDS3$P_V3M*Q0BO MIEVE@Z)&*13]QE X/RCJLD[MS7HQT\PMH5#WDXFO1P[IH=Q1ZL1ZHR^!_T#K MG*I3LU#1"IH+E)(1:AJGYZ%);KO#5>=L/'+K@3S]SI$*2ARE7/290B'\68X4 M<4L3AZML++E_P4NE$,H9I3@,6$-!O1=-->0#"10O2E58:0>UE[A=)C,BIM0_ MCZ):"<6,4B6&S"'WR5-0GSP]L4]&J19]IE )ES/<[6_L?LS9E/A7RP4;@-Z10[#A+0D/V<(#G*3,T+0/K,T%$8LNQ M[0H^3WU?WPJ:!IPUHT#3B(,(WRCG'X5&K.,,9<'7 IH%Q(',L%GD50"J9R]+4QD>MS\00IDC3M^M MM(:(>I@1SF]RS035P=[F0 A%C3A/M](:(NK;C*JI[>P^*+DPL_6*UA!R3P,H M>L39N$&KF"E8_EA/7Z[T"_*O4(/?U8 (WVL2]X4D2>(F=I17>Y$2Y6$?TD/I MHRXD]1M%X7]O9E3MWFD5(0ULS1>:?E'?"IH+E%(7:AKSRKOS7H/@A7=/!Z6. M6-16&<-<$9:/.4OZ7)+@??R>#$H9L8*ML(4(^8:()Y7/3;)Z4#*AU W5Z.WO M#U!& 7< 30QB;7L2"LP'#C++W%(IF3P-9]:ZOL]-\9)8&V7PL4.P'31!F(M6 M <91[Y3TC\5L-+U9/=()56["Q(@NS8T]W%/XQ@G0')HEU+3K MSFYP[P,NOW%_N7?>VBW_ U!+ P04 " "X@"=0O0Z\>VD6 %

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